Navigation
Professor Janusz Jankowski

Prof. Janusz Jankowski

Prof of Medicine and Lead for Clinical Research

School of Medicine

jjankowski@uclan.ac.uk

Subject Areas: Clinical Trials, Genomics and Systematic Evidence Based Reviews, Allied Health, Biosciences, Education, Public Health

Professor Janusz Jankowski leads one of the most successful clinical cancer prevention programmes in the UK on oesophageal cancer.

He has an h-index of 58+ with 14,000+ citations and last year alone had 1,900 citations.

Professor Jankowski is also committed to education and mentoring clinical scientists in designated roles for the British Society Gastroenterology and Royal College Physicians. 

Full Profile

Basic Science. My group elucidated the site and number of stem cells and their progeny in Barrett’s metaplasia (BM) (Gastroenterology 2013). Furthermore we showed that regulation of stem cell plasticity involves nuclear translocation of -catenin (Am J Pathol 1998 & Gut 2008). Moreover stem cell division may be controlled by mucosal inflammation, especially TNF (Oncogene 2002) and cell adhesion (Lab Invest 1999) (Lab Invest 1998) enabling crypt bifurcation and hence clonal expansion (Gut 2012, Cancer Res 2008 & PNAS 2006).

Translational and Genomic Science. I elucidated the epigenetics of the oesophagitis-metaplasia-dysplasia-adenocarcinoma sequence; especially over-expression of the Epidermal Growth Factor Receptor (EGFR) family (Gut 1993) and mutations (Clin Cancer Res 2006). I co-led the application of these findings in large trials addressing EGFR inhibitors in cancer (Lancet Oncology 2014).
My team reported the first Genome Wide Analysis (GWAS) of BM showing predisposition that could perturb inflammatory regulation via obesity (Nature Genet 2012, Gastroenterology 2015 & Lancet 2016). I have contributed to other GWAS; Multiple Sclerosis (Nature 2011), Colitis (Nature Genet 2009), Psoriasis (Nature Genet 2010), Diabetes (Nature Genet 2011), Spondylitis (Nature Genet 2011) and Stroke (NEJM 2012).

Clinical Trials and Systematic Reviews. I set up large intervention trials (BMJ 2010) including the longest prospective randomised chemoprevention trial (AspECT) reporting in 2017. This has influenced the aspirin debate urging caution in primary prevention (Lancet Oncol 2009, Lancet 2009 & Lancet 2011).
I led research improving Clinical Standards with formal NHS endorsement on cancer surveillance (Am J Gastroenterology 2007 & Gastroenterology 2004) and endoscopic quality (Gastroenterology 2006; & Am J Gastroenterology 2008). I led the largest English-Language Consensus Reviews, BADCAT (Gastroenterology 2012) and BOBCAT (Am J Gastroenterology 2015) (both NHS badged).

Janusz co-led an international genetic analysis study into oesophageal cancer, read more now.

QUALIFICATIONs;

Clinical

M.B. Ch.B., (with Clinical Merits) University of Glasgow, 1983
F.R.C.P.E., Clinical Fellow Royal College of Physicians, Edinburgh, 1999
F.R.C.P., Clinical Fellow Royal College of Physicians, London, 2000
Certificate Specialist Register, GI & Medicine General Medical Council , 2867294, Lond, 1997

Research

M.Sc., cum laude, Clinical Trial Research Linacre College, University of Oxford, 2009
M.D., Molecular Medicine Research University of Dundee, 1995
Ph.D., Translational Pathology Research Imperial College, University of London, 1996

Education

F.A.C.G., Fellow Education American College of Gastroenterology, 2007
A.G.A.F., Fellow Education American Gastroenterology Association, 2012
S.F.H.E.A., Senior Fellow Education Higher Education Academy, Plymouth University, 2014
Certificate of Medical Education Madingley Hall, University of Cambridge, 2013
Train the Trainer (Practical Skills) National NHS Endoscopy Centre, 2013

Leadership and Mentoring

Certificates of Mentoring, (Student & Staff) Gerard Egan & Royal Coll Phys, Leicestershire, 2005
Certificate of Leadership, (Team Building) John Adair, University Hospitals, Warwick, 2014
Certificate of Leadership, (Complex Settings) Leadership Foundation Higher Education, London, 2015

Sports and Sports Medicine

1st Dan Black Belt & Certified Instructor Intern’l TaeKwon-Do Federation, GBR-1-2810, 2015
Certificate of Advanced Life Support Resuscitation Council, UK, 2015
Certificate of Concussion Management American College of Sports Medicine, USA, 2014

Finance

Certificate of Finance for General Managers NHS, UHCW, 2016
Certificate of Finance Management & Growth NHS, 2016

Publications

Su Z, ...... Jankowski JA. Common variants at the MHC locus and at 16q24.1 predispose to Barrett’s oesophagus.
Impact: (World’s first genome study of GI pre-malignancy, Web Links > 100, BBC ‘Inside Health’, BBC Radio 4 News).
Nature Genetics 2012;44:1131-6 (Top Science Journal, Impact Factor 36).

2. Bennett CM, …… Jankowski JA. Consensus on the management of Barrett’s dysplasia.
Impact: (World’s largest consensus guideline, iterative web system). NICE (1st accredited GI report), Videocast, Web links >30)
Gastroenterology 2012;143:336-346 (Top GI Journal, Impact Factor 16.5).

3. Pan Q, …… Jankowski JA*. Identification of Lineage-Uncommitted, Long-Lived, Labelled Cells in Human Esophagus. Impact: (World’s first identification of esophageal stem cells), Science Alert, Web Links > 50)
Gastroenterology 2013;144:761-70 (Top GI Journal, Impact Factor 16.5).

4. Palles C, …… Jankowski J*. Polymorphisms Near TBX5 and GDF7 are Associated with Risk for Barrett’s Esophagus. Impact: (Follow up to our previous unique observations showing further inherited links to premalignant disease).
Gastroenterology 2015;148:367-78 (Top GI Journal, Impact Factor 16.5).

5. Gharahkhani P, …… Jankowski J*, Schumacher J*. (* Joint Senior Author) Meta-analysis of loci for 15,00 patients.
Impact: (The largest meta-analyses of upper GI inherited susceptibility)
Lancet Oncology revision resubmitted (Top Medical Journal, Impact Factor 25). 

Membership of professional and learned bodies

  • British Society of Gastroenterology
  • Royal College of Physicians
  • International Society for Diseases of the Esophagus 

Research Activities

I have extensive research experience from Basic Science (stem cell biology), through to Translational Science (genomics) and then Clinical Studies (Epidemiology, Clinical Trials and Systematic Reviews) 

Projects

  • AspECT chemoprevention Trial 2,513 patients
  • ChOPIN tissue biobank 70,000+ specimens
  • Eagle genomics consortia 10,000+ patients 

Teaching Activities and Responsibilities

  • Medical Students
  • Physician Associates 

External Activities

  • Chair of TransCan2 EU Committee
  • Treasurer International Society for Diseases of the Esophagus 

Conferences

  • Invited speaker British Society for Gastroenterology
  • Invited Speaker International Society for Diseases of the Esophagus 

SOCIAL MEDIA

LinkedIn

Facebook